Company Overview
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $42.00K (-76.8% YoY); net profit $-11.44M.
- Trailing 12 Months Year-on-year growth — revenue -76.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -35.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -35.11% |
| 1 Year: | -76.80% |
Stock Price Performance
| 1 Year: | +55.15% |
| 6 Months: | +126.32% |
| 3 Months: | +150.83% |
| 1 Month: | +4.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -35.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ENTX Entera Bio Ltd. PHARMA | 3.01 | -8.60 | $521.16M | 0.00% | -83.60% | -138.92% | -35.11% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 109.00K | 140.00K | 68.00K | 44.00K | 8.00K | 0 | 0 | 0 | 0 | 57.00K | 42.00K | 42.00K | 0 | 0 | 0 | 0 |
| Gross Profit | 84.00K | 10.00K | 75.00K | 14.00K | 11.00K | 2.00K | 0 | 0 | 0 | - | 9.00K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.34M | -2.57M | -3.22M | -3.83M | -3.25M | -2.87M | -2.21M | -2.33M | -2.39M | -2.06M | -2.17M | -3.02M | -2.56M | -2.67M | -3.26M | -3.54M | -4.56M |
| Net Income | -2.30M | -2.58M | -3.21M | -3.78M | -3.19M | -3.07M | -2.19M | -2.33M | -2.38M | -2.02M | -2.15M | -3.02M | -2.57M | -2.66M | -3.20M | -3.50M | -7.31M |
| Diluted EPS | - | 0.10 | 0.11 | 0.13 | 0.11 | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.06 | 0.08 | 0.06 | 0.06 | 0.07 | 0.07 | 0.14 |
| R&D Expense | 1.12M | 1.23M | 1.77M | 1.69M | 1.39M | 1.41M | 931.00K | 1.21M | 1.37M | 735.00K | 1.09M | 1.48M | 1.12M | 1.52M | 1.64M | 2.25M | 3.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 365.00K | 571.00K | 134.00K | 0 | 181.00K | 42.00K |
| Gross Profit | 65.00K | 198.00K | 33.00K | 0 | 9.00K | 0 |
| Operating Income | -11.17M | -12.22M | -13.02M | -8.89M | -9.59M | -11.53M |
| Net Income | -11.22M | -12.19M | -13.07M | -8.89M | -9.54M | -11.44M |
| Diluted EPS | - | 0.47 | 0.45 | 0.31 | 0.25 | 0.25 |
| R&D Expense | 6.38M | 6.77M | 5.85M | 4.51M | 4.50M | 6.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.72M | 25.99M | 13.13M | 11.77M | 9.39M | 15.99M |
| Total Equity | 13.77M | 7.51M | 22.57M | 11.75M | 10.39M | 8.08M | 13.10M |
| Cash & Equivalents | - | 8.59M | 24.89M | 12.31M | 11.02M | 8.66M | 7.11M |
| Total Liabilities | - | 2.21M | 3.42M | 1.37M | 1.38M | 1.31M | 2.89M |
| Current Liabilities | - | 1.84M | 3.16M | 1.34M | 1.09M | 1.18M | 2.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.56M | -9.06M | -12.50M | -7.31M | -6.82M | -7.37M |
| Investing Cash Flow | -53.00K | -17.00K | -102.00K | -17.00K | -3.00K | -107.00K |
| Financing Cash Flow | 4.05M | 25.38M | 13.00K | 6.04M | 4.48M | 13.71M |
| Capital Expenditure | -53.00K | -17.00K | -47.00K | -17.00K | -3.00K | -107.00K |
| Free Cash Flow | -10.61M | -9.08M | -12.55M | -7.33M | -6.82M | -7.48M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 17.8% | 34.7% | 24.6% | - | 5.0% | 0.0% |
| Operating Margin % | -3,059.7% | -2,139.6% | -9,714.2% | - | -5,295.6% | -27,450.0% |
| Net Margin % | -3,072.9% | -2,134.3% | -9,754.5% | - | -5,271.3% | -27,235.7% |
| ROE % | -149.3% | -54.0% | -111.2% | -85.6% | -118.1% | -87.3% |
| ROCE % | -141.7% | -53.5% | -110.4% | -83.3% | -116.7% | -83.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Knoll Capital Management, LLC | 3.38% | 5.88M | $17.41M |
| 2 | BVF Inc. | 1.40% | 2.42M | $7.18M |
| 3 | Siren, L.L.C. | 0.42% | 736.46K | $2.18M |
| 4 | Renaissance Technologies, LLC | 0.21% | 368.85K | $1.09M |
| 5 | PNC Financial Services Group, Inc. | 0.16% | 273.03K | $808.17K |
| 6 | Parkman Healthcare Partners LLC | 0.16% | 274.50K | $812.51K |
| 7 | Seven Fleet Capital Management LP | 0.11% | 191.35K | $566.41K |
| 8 | HighTower Advisors, LLC | 0.04% | 74.57K | $220.74K |
| 9 | HRT Financial LP | 0.04% | 72.49K | $214.56K |
| 10 | Schonfeld Strategic Advisors Llc | 0.03% | 58.87K | $174.26K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENTX
Entera Bio Stock Price Forecast. Should You Buy ENTX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1qQktZdzBUOFFqWXpNanJuZGxsX09leXZqeDhnY3dMaXg3MjlxQS1ZeFFhRmkxTXExQ3FXLWxMRGVwb3VQVGx5NA?oc=5" target="_blank">Entera Bio Stock Price Forecast. Should You Buy ENTX?</a> …
$ENTX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPakUwbVJfS1NIWmFWQi10andLWG5NdG00NXpJN19IbHhqbWgzeUpKdU0xc0VXQkNzRmZGQ3pKdk9IbG5XbzRGVkx6aVhVbW1oOURkSl9kUXdBQ2dEOHV2QWs5Q19FUlh1R08xdE1rTEQwcmg3eGZaenNQUlhLRVBLVDlQV2lwc1dIaFdpcm…
A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPOTZEemc0M3JMQ20wVmcwZ3ZMajN4RERCelNhU2hGYzZNX1dTbjBKY011NXNNWFdadXVXaHNWZmNHMkxPWXBFdU52cllBcGR5alBoOEliZHYtUmk3TTgzTW5ZSWdCNm0xajQ4TzlNeURjb1hta1lPTDF2R0NkLXJOMEJ5ejJEaTBCTUNCMn…
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPTFNpNVl6ak90VTVFZnJQVFBNNnJsRXhYQS1oVkJIcW5hWDRXOGZMc3IwSG5Takt0enNyX0JoXzk4U0hjcVlDMUJuMndqazc5WjdBMS0xZWhoNGlRQTMwbUtURzdTc0dQOV9wa1dyc2hreEFJRHZtdnZvX2NxT2RwQVBLRlNJaFhsMFZQSn…
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNMXBNSW12S05zay1oTTVUbjBTd09abEFDY2Q1UXZuOFRWb1FScm0tYVlndjBzUlM3R3BvZVhJUXlkdUxYQmV3b0NsLWdtQ01lbWc0WkVJakJGVWVhM2E3Yi10SFRrclMzVy02YnZ3eTBnaEdSUHBKeU1jVGJqQnRMVUx0SEgzNlVNNDNRbF…
ENTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5mUngtZnQ0YzJiZk5HeUJnVFN0UHF3MGk3MTh2MHRYbEF3a2xtX2pDVmM5cGVEdy02YWFrU1VyamN6M04xUlE?oc=5" target="_blank">ENTX</a> <font color="#6f6f6f">Finviz</font>…
ENTX — Frequently Asked Questions
What is the current share price of Entera Bio Ltd. (ENTX)?
As of 2026-09-19 21:16 PDT, Entera Bio Ltd. (ENTX) trades at $3.01 on NasdaqCM. Its 52-week range is $1.00 to $3.92.
What is the market capitalisation of ENTX?
Entera Bio Ltd. (ENTX) has a market capitalisation of $521.16M on NasdaqCM.
What is the P/E ratio of ENTX?
ENTX trades at a trailing price-to-earnings (P/E) ratio of -8.60. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 19.32.
What is the return on equity (ROE) of ENTX?
ENTX has a return on equity (ROE) of -138.92%. Its return on capital employed (ROCE) is -83.60%.
Is ENTX a good stock to buy?
This page provides a data-driven analysis of Entera Bio Ltd. (ENTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.